Table 1.
Baseline characteristicsa
| Patient characteristic | Metronidazole treatment (n = 15) | Placebo treatment (n = 16) | Total (n = 31) |
|---|---|---|---|
| Age in yrs, median (IQR) | 36 (28, 39) | 38 (31, 44) | 37 (30, 43) |
| Male, n (%) | 13 (87) | 12 (75) | 25 (81) |
| Body-mass index, median (IQR) | 19 (18, 20) | 19 (18, 22) | 19 (18, 21) |
| Diabetes mellitus, n (%) | 1 (7) | 2 (13) | 3 (10) |
| Previous TB episodes, median n (IQR) | 2 (1, 5) | 3 (2, 3) | 2 (1, 3) |
| Resistant drugs, median n (IQR) | 4 (3, 6) | 5 (4, 6) | 4 (4, 6) |
| Active drugs in regimen, median n (IQR) | 4 (4, 5) | 5 (4, 5) | 5 (4, 5) |
| Fluoroquinolone resistance, n (%) | 5 (33) | 6 (38) | 11 (35) |
| Far advanced disease,b n (%) | 5 (33) | 10 (63) | 15 (48) |
| Cavitary disease by CXR, n (%) | 6 (40) | 10 (63) | 16 (52) |
| Bilateral disease by CXR, n (%) | 9 (60) | 12 (75) | 21 (68) |
a
There were no statistical differences in baseline characteristics between the two arms. CXR, chest X ray.
b
“Far advanced tuberculosis” was defined according to the guidelines of the Korea Centers for Disease Control and Prevention as the presence of disseminated lesions of slight-to-moderate density exceeding the total volume of one lung, or dense and confluent lesions exceeding one-third the volume of one lung, or the presence of cavities greater than 4 cm in diameter.